Sixteen-year-old Anthony Melena is an avid history buff. And a sports buff. And he loves to travel. So imagine the thrill he experienced in September when he went to Beijing, China, as part of an American delegation at the 2008 Paralympic Games. “I guess I was speechless (when I heard...
Latest News
LAWRENCEVILLE, N.J. — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in...
San Diego, Calif. – About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain. And metastasis relies on cancer cells’ ability to...
POMEZIA, Italy – The Menarini Group announced today that additional data have been generated on SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3 inhibitor, as part of the DIAMOND-01 trial. The results will be presented at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses. DIAMOND-01...
FLORENCE, Italy – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in...
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. – Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on multiple myeloma (MM). This new CELLSEARCH® Circulating Multiple Myeloma Cells (CMMCs) Assay* captures...
RAHWAY, N.J. — Merck & Co. (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated...
RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell...
DARMSTADT, Germany – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant...
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational...